GLYMOUR, M. M.; BRICKMAN, A. M.; KIVIMAKI, M.; MAYEDA, E. R.; CHENE, Geneviève; DUFOUIL, Carole; MANLY, J. J.

doi:10.1007/s10654-018-0418-4

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

Idioma

Article de revue

Este ítem está publicado en

European Journal of Epidemiology. 2018-07, vol. 33, n° 7, p. 607-612

Resumen en inglés

A recently published framework for the diagnosis of Alzheimer's disease (AD) in research studies would allow diagnosis on the sole basis of two biomarkers (beta-amyloid and pathologic tau), even in people with no objective or subjective memory or cognitive changes. This revision will have substantial implications for future Alzheimer's research, and the changes should be rigorously evaluated before widespread adoption. We propose three principles for evaluating any revision to diagnostic frameworks for AD: (1) does the revision improve the validity of the diagnosis; (2) does the revision improve the reliability or reduce the expense of the diagnosis; and (3) will the revision foster innovative and rigorous research across populations. The new diagnostic framework is unlikely to achieve any of these goals. Instead, it has the potential to handicap future researchers, and slow progress towards identifying effective strategies to prevent or treat AD.< Leer menos

Palabras clave en inglés

MORPH3Eus

CIC1401

VINTAGE

Metadatos

Compartir este ítem

Licencia de uso del documento

Will biomarker-based diagnosis of Alzheimer's disease maximize scientific progress? Evaluating proposed diagnostic criteria

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación